The authors thank Winona Wright for study coordination and technical assistance with this article; the NIH-supported Consortium for the Study of Chronic Pancreatitis, Diabetes, and Pancreatic Cancer for helpful suggestions and ancillary study status; and the PanCAN Early Detection Initiative participants and investigators for their important contributions to the development of effective pancreatic cancer screening strategies.
Howlader N, Noone A, Krapcho M, et al. , eds. SEER cancer statistics review, 1975–2017. Accessed December 23, 2020. Available at: https://seer.cancer.gov/csr/1975_2017/
Katz MHG, Hu CY, Fleming JB, et al. Clinical calculator of conditional survival estimates for resected and unresected survivors of pancreatic cancer. Arch Surg 2012;147:513–519.
Pannala R, Basu A, Petersen GM, et al. New-onset diabetes: a potential clue to the early diagnosis of pancreatic cancer. Lancet Oncol 2009;10:88–95.
Chari ST, Leibson CL, Rabe KG, et al. Probability of pancreatic cancer following diabetes: a population-based study. Gastroenterology 2005;129:504–511.
Sharma A, Kandlakunta H, Nagpal SJS, et al. Model to determine risk of pancreatic cancer in patients with new-onset diabetes. Gastroenterology 2018;155:730–739.e3.
Sanders GD, Neumann PJ, Basu A, et al. Recommendations for conduct, methodological practices, and reporting of cost-effectiveness analyses: second panel on cost-effectiveness in health and medicine. JAMA 2016;316:1093–1103.
Rocca WA, Yawn BP, St Sauver JL, et al. History of the Rochester Epidemiology Project: half a century of medical records linkage in a US population. Mayo Clin Proc 2012;87:1202–1213.
Maitra A, Sharma A, Brand RE, et al. A prospective study to establish a new-onset diabetes cohort: from the Consortium for the Study of Chronic Pancreatitis, Diabetes, and Pancreatic Cancer. Pancreas 2018;47:1244–1248.
Wright AK, Kontopantelis E, Emsley R, et al. Life expectancy and cause-specific mortality in type 2 diabetes: a population-based cohort study quantifying relationships in ethnic subgroups. Diabetes Care 2017;40:338–345.
Billings BJ, Christein JD, Harmsen WS, et al. Quality-of-life after total pancreatectomy: is it really that bad on long-term follow-up? J Gastrointest Surg 2005;9:1059–1067.
Corral JE, Das A, Bruno MJ, et al. Cost-effectiveness of pancreatic cancer surveillance in high-risk individuals: an economic analysis. Pancreas 2019;48:526–536.
Bonomi AE, Boudreau DM, Fishman PA, et al. Quality of life valuations of mammography screening. Qual Life Res 2008;17:801–814.
Choi JG, Nipp RD, Tramontano A, et al. Neoadjuvant FOLFIRINOX for patients with borderline resectable or locally advanced pancreatic cancer: results of a decision analysis. Oncologist 2019;24:945–954.
Meng Y, McCarthy G, Berthon A, et al. Patient-reported health state utilities in metastatic gastroenteropancreatic neuroendocrine tumours—an analysis based on the CLARINET study. Health Qual Life Outcomes 2017;15:131.
Centers for Medicare & Medicaid Services. Physician fee schedule search. Accessed December 23, 2020. Available at: https://www.cms.gov/apps/physician-fee-schedule/search/search-criteria.aspx
Tramontano AC, Chen Y, Watson TR, et al. Pancreatic cancer treatment costs, including patient liability, by phase of care and treatment modality, 2000-2013. Medicine (Baltimore) 2019;98:e18082.
Li R, Bilik D, Brown MB, et al. Medical costs associated with type 2 diabetes complications and comorbidities. Am J Manag Care 2013;19:421–430.
Bhulani N, Gupta A, Gao A, et al. Palliative care and end-of-life health care utilization in elderly patients with pancreatic cancer. J Gastrointest Oncol 2018;9:495–502.
TRIAD Study Group. The Translating Research Into Action for Diabetes (TRIAD) study: a multicenter study of diabetes in managed care. Diabetes Care 2002;25:386–389.
Keehan SP, Cuckler GA, Poisal JA, et al. National health expenditure projections, 2019-28: expected rebound in prices drives rising spending growth. Health Aff (Millwood) 2020;39:704–714.
Clemens K, Garrison LP Jr, Jones A, et al. Strategic use of pharmacoeconomic research in early drug development and global pricing. Pharmacoeconomics 1993;4:315–322.
Steuten LM, Ramsey SD. Improving early cycle economic evaluation of diagnostic technologies. Expert Rev Pharmacoecon Outcomes Res 2014;14:491–498.
Chen W, Butler RK, Lustigova E, et al. Validation of the enriching new-onset diabetes for pancreatic cancer model in a diverse and integrated healthcare setting. Dig Dis Sci 2021;66:78–87.
Ginde AA, Foianini A, Renner DM, et al. Availability and quality of computed tomography and magnetic resonance imaging equipment in U.S. emergency departments. Acad Emerg Med 2008;15:,780–783.